Posts tagged with ‘collaborators’

  • Jeffrey Schlom, PhD

    - by Syntrix

    Chief of Laboratory of Tumor Immunology and Biology at NCI. Principal Investigator on awarded Syntrix-NCI CRADA to fund SX-682 through Phase II.

  • Elizabeth Mittendorf, MD, PhD

    - by Syntrix

    Surgical oncologist focused on breast cancer immunotherapy. Principal Investigator and key design lead of SX-682 Phase I/II breast cancer trial.

  • Rami Komrokji, MD

    - by Syntrix

    Professor and head of the Leukemia and MDS Section at the Moffitt Cancer Center. Principal Investigator of SX-682 MDS Phase I/II trial.

  • McGarry Houghton, MD

    - by Syntrix

    Expert on tumor microenvironment and host immune response in lung cancer.

  • Dimitry Gabrilovitch, MD, PhD

    - by Syntrix

    Leads Wistar’s Translational Tumor Immunology Program. MDSC pioneer and co-investigator in SX-682 melanoma trial.

  • Keith Flaherty, MD

    - by Syntrix

    IO thought leader in melanoma. PI of SX-682 Phase I/II melanoma trial.

  • Ronald DePinho, MD

    - by Syntrix

    Partner laboratory on SX-682 prostate cancer Nature paper. Former President of MD Anderson Cancer Center.

  • Martin “Mac” Cheever, MD

    - by Syntrix

    Principal Investigator of the National Cancer Institute-funded Cancer Immunotherapy Trials Network.

Bitnami